Hamburg

• Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line t … Ended recruitment
  2024-517965-18-00 4 2021-11-11 Advanced NSCLC with common EGFR-Mutation
• A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended recruitment
  2023-506518-33-00 5 2021-11-10 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria Ended recruitment
  2023-509843-28-00 5 2021-11-10 Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Efficacy of Abatacept vs Adalimumab in Early, Autoantibody positive Rheumatoid Arthritis (RA) and who did not respond well to methotrexate. Ended recruitment
  2023-506450-20-00 5 2021-11-05 Rheumatoid Arthritis
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506257-37-00 5 2021-10-29 Active Psoriatic Arthritis
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET Driven, Unresectable and Locally Advanced or Metastatic PRCC … Ended recruitment
  2022-503105-38-00 5 2021-10-22 MET-driven, unresectable and locally advanced or metastatic Papillary
• A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended recruitment
  2023-507130-24-00 5 2021-10-22 Neovascular age-related macular degeneration (nAMD)
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma
• Study on an Investigational Yellow Fever Vaccine Compared with Stamaril in Adults in Europe and Asia Ended recruitment
  2022-502047-35-00 4 2021-10-07 Yellow fever
• A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun … Ended recruitment
  2023-507494-18-00 5 2021-09-24 Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosin
• A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible fo … Ended recruitment
  2024-516959-40-00 4 2021-08-17 This trial evaluates the efficacy and safety of Mirvetuximab soravtans
• A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len … Ended recruitment
  2023-505850-16-00 5 2021-08-05 Multiple Myeloma
• DALY 2-EU Ended recruitment
  2023-506270-13-00 4 2021-07-27 Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)
• A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended recruitment
  2022-502100-70-00 10 2021-06-23 Participants with Microsatellite Instability-High (MSI-H) or Mismatch
• Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended recruitment
  2024-514473-21-00 5 2021-06-21 Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello- … Ended recruitment
  2023-504997-39-00 5 2021-06-14 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
• Long-term safety of apraglutide in short bowel syndrome Ended recruitment
  2023-510389-28-00 5 2021-06-14 short bowel syndrome
• Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive … Ended recruitment
  2023-505249-24-00 5 2021-05-27 HER2-positive metastatic breast cancer
• A study to evaluate the safety and tolerability of seladelpar in subjects with primary biliary cholangitis Ended recruitment
  2024-511753-22-00 5 2021-05-26 Primary Biliary Cholangitis
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• A research study to find out if the study treatment alpelisib (BYL719) is safe and can help others who have confirmed diagnosis of PIK3CA-re … Ended recruitment
  2023-508530-34-00 4 2021-04-19 PIK3CA-Related Overgrowth Spectrum (PROS)
• A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac … Ended recruitment
  2024-514467-26-00 4 2021-04-07 Indolent Systemic Mastocytosis
• A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juven … Ended recruitment
  2023-507184-19-00 5 2021-02-22 Juvenile Psoriatic Arthritis  Enthesitis Related Arthritis
• A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi … Ended recruitment
  2023-509516-28-00 4 2021-02-22 Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col

Showing 721–744 of 1,087 trials